Interleukin-1 (IL-1) is a potent pro-inflammatory cytokine family consisting primarily of IL-1α and IL-1β, produced by activated macrophages, monocytes, epithelial cells, and other innate immune cells in response to PAMPs and DAMPs. It functions as a master orchestrator of the acute inflammatory response, driving fever, acute phase response, immune cell recruitment, and pain sensitization, while simultaneously serving as a critical messenger in the immune-to-brain signaling network that coordinates sickness behaviour. IL-1 operates through the IL-1 receptor type I (IL-1R1), initiating a MyD88-dependent signaling cascade that activates NF-κB and drives transcription of hundreds of inflammatory genes.
Think of IL-1 as the emergency broadcast system that activates when your body's smoke detectors (pattern recognition receptors) sense danger. When macrophages detect PAMPs from invading bacteria or DAMPs from damaged tissue, they don't just release IL-1—they assemble a specialized activation platform (the NLRP3 inflammasome) that acts like a quality control checkpoint. This platform contains a molecular scissor (caspase-1) that cuts the inactive pro-IL-1β into its active, alarm-sounding form—ensuring false alarms don't trigger system-wide panic.
Once released, IL-1 molecules are like urgent text messages broadcast to multiple departments simultaneously: they tell blood vessels to become sticky so immune cells can exit circulation and reach the battlefield, they signal the Liver factory to shift production to emergency proteins like C-reactive protein, they instruct the Hypothalamus thermostat to raise body temperature (making the environment hostile to pathogens), and they activate the HPA axis to mobilize energy reserves via Cortisol. But here's the critical design: the body also releases IL-1 receptor antagonist (IL-1RA)—like sending "all clear" messages right behind the alarms—to prevent the system from spiraling into chronic activation. When this balance fails and alarms keep sounding without genuine threats (chronic inflammation), you get the persistent fatigue, pain, metabolic dysfunction, and mood disturbances that characterize modern inflammatory diseases.
IL-1 production and signaling occurs through a tightly regulated multi-step process:
Two-Signal Activation Model:
- Signal 1 (Priming): TLR4 or other pattern recognition receptors detect PAMPs or DAMPs → activate NF-κB → transcription of pro-IL-1β (inactive precursor)
- Signal 2 (Activation): Secondary danger signals (ATP, uric acid crystals, ROS, potassium efflux) → activate NLRP3 inflammasome → recruits ASC adaptor protein → activates caspase-1 → cleaves pro-IL-1β to bioactive IL-1β
IL-1α vs IL-1β:
- IL-1α: Constitutively expressed, active without cleavage, primarily acts as membrane-bound "danger" signal on stressed/dying cells
- IL-1β: Requires Inflammasome activation, secreted form, primary systemic mediator
IL-1 Receptor Signaling:
graph TD
A["IL-1β binds IL-1R1"] --> B[Recruits IL-1RAcP co-receptor]
B --> C[MyD88 recruitment]
C --> D[IRAK1/2/4 activation]
D --> E[TRAF6 polyubiquitination]
E --> F[TAK1 activation]
F --> G1[IKK complex activation]
F --> G2[MKK activation]
G1 --> H1["IκB degradation"]
H1 --> I1["NF-κB nuclear translocation"]
I1 --> J[Inflammatory gene transcription]
G2 --> H2[p38 MAPK activation]
H2 --> J
G2 --> H3[JNK activation]
H3 --> J
J --> K1["IL-6, IL-8, TNF-α"]
J --> K2[COX-2, PGE2]
J --> K3[Adhesion molecules ICAM-1, VCAM-1]
J --> K4[Chemokines CCL2, CXCL1]
Systemic Effects:
-
Fever induction: IL-1 crosses blood-brain barrier at circumventricular organs or signals via vagal afferents → activates Cyclooxygenase-2 (COX-2) in hypothalamic endothelium → PGE2 synthesis → binds EP3 receptors on thermoregulatory neurons in preoptic area → raises temperature set point by 1-4°C
-
Acute phase response: IL-1 acts synergistically with IL-6 on hepatocytes → JAK-STAT3 signaling → transcription of acute phase proteins (CRP >100 mg/L, serum amyloid A, fibrinogen, haptoglobin) while down-regulating albumin and transferrin
-
HPA axis activation: IL-1 stimulates CRH release from Hypothalamus → ACTH from pituitary → Cortisol release (can reach 500-700 nmol/L during severe infection vs. 200-600 nmol/L morning baseline)
-
Pain sensitization: IL-1 in dorsal root ganglia → sensitizes TRPV1 channels → lowers activation threshold of nociceptors (primary hyperalgesia); IL-1 in spinal cord dorsal horn → enhances glutamate signaling and reduces inhibitory tone (secondary hyperalgesia)
-
Metabolic reprogramming: IL-1 phosphorylates IRS-1 at serine residues → blocks insulin receptor signaling → insulin resistance → preferential glucose shunting to immune cells
Negative Regulation:
- IL-1RA (naturally produced receptor antagonist, ratio IL-1RA:IL-1β should be >10:1)
- SOCS3 proteins inhibit downstream signaling
- Cortisol suppresses IL-1 gene transcription via GR binding to promoter
- Soluble decoy IL-1R2 receptors bind IL-1 without signaling
IL-1 represents a central node in cPNI understanding of how immune activation translates into the constellation of symptoms that patients experience across multiple organ systems—a perfect illustration of the selfish immune system prioritizing its survival needs over comfort and long-term health.
Acute Infection and Sickness Behaviour:
IL-1 is the primary mediator of sickness behaviour—the coordinated suite of behavioral changes during infection including fatigue (energy conservation for immune function), anorexia (prevent pathogen access to nutrients like iron), hyperalgesia (promote rest and healing), social withdrawal, and cognitive slowing. These are not side effects but adaptive strategies, demonstrating evolutionary prioritization of immediate survival over social or reproductive function. Patients experiencing these symptoms without active infection likely have chronic IL-1 elevation.
Chronic Inflammatory Conditions:
Persistent IL-1 signaling drives pathology in:
- Type 2 Diabetes: Chronic nutrient excess activates NLRP3 inflammasome via ceramides and ROS → IL-1β production in adipocytes and pancreatic islets → beta-cell dysfunction and insulin resistance. Clinical threshold: IL-1β >2 pg/mL associated with 2.5-fold increased diabetes risk
- Cardiovascular disease: IL-1β from macrophage-rich atherosclerotic plaques drives continued inflammation. CANTOS trial showed IL-1β inhibition reduced cardiovascular events by 15%
- Depression: IL-1 activates IDO enzyme → tryptophan shunted to kynurenine pathway instead of serotonin → produces neurotoxic quinolinic acid. IL-1β >3.5 pg/mL predicts treatment-resistant depression
- Neuroinflammation: IL-1 from activated microglia drives synaptic pruning, reduces neuroplasticity, impairs hippocampus-dependent memory. Links to Alzheimer's Disease, Parkinson's Disease, and cognitive decline
Metamodel Connections:
- Metamodel 0 (Evolutionary Mismatch): Chronic IL-1 elevation reflects mismatch between evolved acute-response mechanisms and modern chronic stressors (processed foods, chronic psychological stress, sedentary behavior, sleep deprivation)
- Metamodel 1 (Barrier Function): IL-1 both responds to and exacerbates barrier dysfunction—creating feed-forward loops where gut permeability → IL-1 → further barrier damage
- Metamodel 3 (Metabolic Flexibility): IL-1-induced insulin resistance acutely adaptive (shunt glucose to immune cells) but chronically maladaptive
- Metamodel 5 (Psychoneuroimmunology): IL-1 is the primary immune-to-brain messenger, explaining why physical illness produces psychological symptoms
Clinical Interventions:
Direct IL-1 targeting:
- Anakinra (IL-1RA analogue): FDA-approved for autoinflammatory diseases, showing promise in diabetes (reduced HbA1c by 0.4-0.6%), heart failure, and COVID-19
- Canakinumab (anti-IL-1β antibody): Reduced cardiovascular events and potentially cancer incidence
Upstream inflammasome inhibition:
Downstream resolution enhancement:
Clinical Thresholds:
- Serum IL-1β <1 pg/mL: Normal baseline
- IL-1β 2-5 pg/mL: Low-grade chronic inflammation, metabolic risk
- IL-1β >10 pg/mL: Active inflammatory disease
- IL-1RA:IL-1β ratio <10:1: Inadequate counter-regulation
- IL-1β requires two sequential signals: priming (transcription) and activation (Inflammasome cleavage)—preventing inappropriate activation
- Caspase-1 cleaves pro-IL-1β (31 kDa) at Asp116 to produce mature IL-1β (17 kDa)
- IL-1 is one of the most potent pyrogens: as little as 1 ng/kg can induce fever in humans
- Half-life of circulating IL-1β is only 6 minutes—effects mediated through sustained production rather than accumulation
- IL-1α remains cell-associated in >80% of cases, functioning as "danger signal" when cells die; IL-1β is actively secreted
- IL-1RA is produced 100-fold excess over IL-1 during healthy acute inflammation—chronic disease shows inadequate IL-1RA response
- PGE2-induced fever peaks 30-60 minutes after IL-1 exposure, coinciding with peak prostaglandin synthesis
- IL-1 synergizes with TNF-α—combination produces 10-100x greater inflammatory response than either alone
- Genetic polymorphisms in IL-1 gene cluster (2q13) affect production: IL-1B -511 T allele associated with 4-fold higher production
- Cortisol normally suppresses IL-1 via GR-mediated transcriptional repression—glucocorticoid resistance allows persistent IL-1 production
- IL-1 induces its own inhibitors (IL-10, IL-1RA, soluble IL-1R2) as negative feedback—failure of this mechanism drives chronicity
- NLRP3 inflammasome can be activated by metabolic danger signals: ceramides, cholesterol crystals, AGEs, uric acid crystals, amyloid-β
- NLRP3 inflammasome — activated inflammasome complex that cleaves pro-IL-1β to bioactive form via caspase-1; central to metabolic inflammation
- caspase-1 — cysteine protease that cleaves pro-IL-1β at Asp116, producing mature 17 kDa IL-1β; also processes IL-18 and gasdermin D (pyroptosis)
- macrophages — primary cellular source; M1 polarization maximizes IL-1 production, M2 polarization favors IL-1RA
- monocytes — circulating precursors that produce IL-1 upon tissue infiltration; CD14+CD16+ "inflammatory" subset produces highest IL-1
- DAMPs — endogenous danger signals (HMGB1, ATP, uric acid, HSPs) that activate NLRP3 inflammasome triggering IL-1β release
- PAMPs — pathogen molecules (LPS, flagellin, bacterial RNA/DNA) that prime IL-1 production via TLR signaling and NF-κB activation
- fever — IL-1 crosses blood-brain barrier at circumventricular organs, induces COX-2 and PGE2 in hypothalamic endothelium, raising temperature set point
- NF-κB — master transcription factor activated by IL-1R1 signaling; drives expression of >500 inflammatory genes including IL-6, TNF-α, COX-2
- acute phase response — IL-1 stimulates hepatic production of CRP, SAA, fibrinogen, haptoglobin while suppressing albumin and transferrin
- sickness behaviour — IL-1 induces constellation of fatigue, anorexia, hyperalgesia, social withdrawal, cognitive slowing via direct brain effects and vagal signaling
- HPA axis — IL-1 activates hypothalamic CRH neurons triggering ACTH and cortisol release; chronic IL-1 can cause HPA axis dysregulation
- COX-2 — IL-1 induces cyclooxygenase-2 expression, driving PGE2 synthesis for fever and pain sensitization; target of NSAIDs
- IL-6 — synergistic partner to IL-1 in acute phase response; IL-1 primes hepatocytes for IL-6 responsiveness
- Interleukin-6 — together with IL-1, drives hepatic acute phase protein production; IL-6 more sustained, IL-1 more rapid
- TNF-α — acts synergistically with IL-1 in inflammatory cascade; combination produces amplified NF-κB activation and endothelial activation
- neutrophils — recruited by IL-1-induced chemokines (CXCL1, IL-8) and adhesion molecules (ICAM-1, VCAM-1); IL-1 primes for enhanced ROS production
- insulin resistance — IL-1 phosphorylates IRS-1 at serine residues (Ser307), blocking insulin receptor signaling; mechanism linking inflammation to metabolic disease
- Depression — IL-1 activates IDO enzyme shunting tryptophan to kynurenine pathway, reducing serotonin and producing neurotoxic metabolites
- pain — IL-1 in DRG and spinal dorsal horn sensitizes nociceptors via NGF upregulation, TRPV1 sensitization, and enhanced glutamate signaling
- Type 2 Diabetes — NLRP3/IL-1β axis links obesity and nutrient excess to beta-cell dysfunction; IL-1β inhibition improves glycemic control
- cardiovascular disease — IL-1β from atherosclerotic plaques drives continued inflammation; CANTOS trial showed anti-IL-1β reduced events
- IL-1 receptor — type I receptor (IL-1R1) mediates signaling via MyD88; type II receptor (IL-1R2) is decoy receptor without signaling domain
- Cortisol — glucocorticoids suppress IL-1 gene transcription; cortisol resistance allows persistent IL-1 production despite elevated cortisol
- PGE2 — prostaglandin produced downstream of IL-1-induced COX-2; mediates fever via EP3 receptors in hypothalamus
- IL-10 — key anti-inflammatory cytokine that suppresses IL-1 production and signaling; IL-10 deficiency allows unchecked IL-1 activity
- HMGB1 — alarmin DAMP released by necrotic cells that activates NLRP3 and primes IL-1 production; amplifies inflammation
- gut permeability — IL-1 increases intestinal permeability via effects on tight junctions, creating feed-forward loop where barrier dysfunction → IL-1 → further barrier damage
- neuroinflammation — microglial IL-1 impairs synaptic plasticity, reduces BDNF, activates IDO; links peripheral inflammation to cognitive and mood symptoms
- Hypothalamus — IL-1 signals to hypothalamic neurons via circumventricular organs and vagal pathways; induces fever, activates HPA axis, suppresses appetite
- chronic inflammation — persistent IL-1 elevation defines chronic low-grade inflammation; when IL-1RA response inadequate, drives chronic disease
- obesity — adipocyte hypertrophy → ER stress and hypoxia → NLRP3 activation → IL-1β production from adipose tissue macrophages
- Alzheimer's Disease — IL-1 from activated microglia enhances amyloid-β production, tau phosphorylation, and synaptic dysfunction
- Exercise — acute exercise induces transient IL-1 but also muscle-derived IL-1RA and IL-10, improving IL-1RA:IL-1β ratio long-term
- Module 1: Introduction to immunology and cytokine biology; IL-1 as prototypical pro-inflammatory cytokine
- Module 4: Neuroendocrinology and immune-to-brain signaling; IL-1 in HPA axis activation and sickness behaviour